Analysis of the factors associated with Tc-99m pertechnetate uptake in thyrotoxicosis and graves' disease.
To determine the factors associated with 20 minute Tc-99m pertechnetate thyroid uptake, we examined all patients in whom thyrotoxicosis was diagnosed at Chiba-Hokusoh Hospital, Nippon Medical School from 2001 April through 2003 March. Patients with thyrotoxicosis diagnosed during this period were 57 with Graves' disease (76%), 11 with transient hyperthyroxinemia (TH)(14.7%), and 7 with subacute thyroiditis (SAT)(9.3%). The uptake of Tc-99m ranged from 0.97% to 40.1% in Graves' disease and from 0.15% to 0.8% in TH. Although TH may include spontaneous resolution of Graves' disease as well as painless thyroiditis, no treatment was necessary for these patients. Uptake in all patients with SAT was less than 0.5%. There were significant correlations between the level of Tc-99m uptake and the levels of free triiodothyronine (fT3), free thyroxine (fT4), thyroid-stimulating hormone (TSH)-binding inhibitory immunoglobulin (TBII), and thyroid stimulating antibody (TSAb) in patients with Graves' disease. Older patients with Graves' disease showed lower uptake than did younger patients. Both Tc-99m pertechnetate uptake and TBII levels, but not fT3, fT4 or TSAb levels, at the beginning of antithyroid drug treatment correlated significantly with the duration of treatment until the daily dose of methimazole reached 5 mg. These data suggest that Tc-99m pertechnetate uptake reflects the severity of Graves' disease and its response to the medical treatment and that antithyroid drug therapy is not necessary when the uptake is less than 0.9%.
Kidokoro-Kunii
Yo
Y
Department of Medicine, Chiba-Hokusoh Hospital, Nippon Medical School, 1715 Kamagari, Inba-gun, Inba-mura, Japan.
Emoto
Naoya
N
Cho
Keiichi
K
Oikawa
Shinichi
S
D000368:Aged; D003937:Diagnosis, Differential; D005260:Female; D006111:Graves Disease / Q000000981:diagnostic imaging*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000378:metabolism; D013670:Sodium Pertechnetate Tc 99m / Q000378:metabolism; D013961:Thyroid Gland / Q000000981:diagnostic imaging / Q000378:metabolism; D013971:Thyrotoxicosis / Q000000981:diagnostic imaging*
D019275:Radiopharmaceuticals; D013670:Sodium Pertechnetate Tc 99m